1. Home
  2. SAIH vs CHRO Comparison

SAIH vs CHRO Comparison

Compare SAIH & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAIH
  • CHRO
  • Stock Information
  • Founded
  • SAIH 2019
  • CHRO 2002
  • Country
  • SAIH Singapore
  • CHRO United States
  • Employees
  • SAIH N/A
  • CHRO N/A
  • Industry
  • SAIH
  • CHRO
  • Sector
  • SAIH
  • CHRO
  • Exchange
  • SAIH NYSE
  • CHRO Nasdaq
  • Market Cap
  • SAIH 13.4M
  • CHRO 10.7M
  • IPO Year
  • SAIH N/A
  • CHRO 2024
  • Fundamental
  • Price
  • SAIH $4.55
  • CHRO $1.45
  • Analyst Decision
  • SAIH
  • CHRO Strong Buy
  • Analyst Count
  • SAIH 0
  • CHRO 1
  • Target Price
  • SAIH N/A
  • CHRO N/A
  • AVG Volume (30 Days)
  • SAIH 17.4K
  • CHRO 8.2K
  • Earning Date
  • SAIH 04-22-2025
  • CHRO 03-27-2025
  • Dividend Yield
  • SAIH N/A
  • CHRO N/A
  • EPS Growth
  • SAIH N/A
  • CHRO N/A
  • EPS
  • SAIH N/A
  • CHRO N/A
  • Revenue
  • SAIH $6,954,000.00
  • CHRO N/A
  • Revenue This Year
  • SAIH N/A
  • CHRO N/A
  • Revenue Next Year
  • SAIH N/A
  • CHRO N/A
  • P/E Ratio
  • SAIH N/A
  • CHRO N/A
  • Revenue Growth
  • SAIH N/A
  • CHRO N/A
  • 52 Week Low
  • SAIH $3.07
  • CHRO $0.45
  • 52 Week High
  • SAIH $26.99
  • CHRO $3.80
  • Technical
  • Relative Strength Index (RSI)
  • SAIH N/A
  • CHRO 43.38
  • Support Level
  • SAIH N/A
  • CHRO $1.34
  • Resistance Level
  • SAIH N/A
  • CHRO $2.00
  • Average True Range (ATR)
  • SAIH 0.00
  • CHRO 0.17
  • MACD
  • SAIH 0.00
  • CHRO -0.02
  • Stochastic Oscillator
  • SAIH 0.00
  • CHRO 16.58

About SAIH SAIHEAT LIMITED

Saiheat Ltd develops technologies for the advanced Computing Center Ecosystem (ACCE), a next-gen computing center featuring high-performance servers, advanced liquid cooling, and systems for capturing and recycling computing heat. It aims to reduce the carbon footprint of Bitcoin mining and AI operations.

About CHRO Chromocell Therapeutics Corporation

Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Share on Social Networks: